Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAS p21 protein activator 4B (RASA4B)
- Target
- RASA4B
- Molecular classification
- Enzyme (specifically, GTPase-activating protein/GAP), Signal transduction regulator, Metal ion and phospholipid binding protein
01
Overview
RAS p21 protein activator 4B (RASA4B) is a Ca2+-dependent GTPase-activating protein that dampens Ras protein signal transduction by promoting the conversion of Ras from its active GTP-bound state to an inactive GDP-bound form. This protein localizes to the cytosol and plasma membrane, especially upon increased intracellular calcium, and participates in the negative regulation of the Ras-MAPK signaling pathway. RASA4B activities are important for control of cell proliferation, differentiation, and apoptosis; aberrant regulation or mutation of RASA4B is implicated in tumorigenesis and other pathological conditions where Ras signaling is dysregulated
- Other names
- RASA4BRas GTPase-activating protein 4BRAS p21 protein activator 4B
02
Mechanism of action
For drugs or research agents, mechanisms would include inhibition of RASA4B activity or modulation of its expression, leading to altered Ras pathway signaling
03
Biological functions
Negative regulation of Ras signal transductionGTPase activator activity (promoting inactivation of Ras proteins)Cellular response to calcium ionsIntracellular signal transductionRegulation of cell proliferation, differentiation, and apoptosis
04
Disease associations
Cancer (implicated in several cancer types through aberrant Ras signaling)Potential association with Hemoglobin H disease
05
Safety considerations
No clinical safety concerns are documented for direct modulation of RASA4B, as no drugs are currently in clinical use; theoretical concerns would relate to disruption of cell proliferation and apoptosis regulation
06
Interacting drugs
There are currently no approved drugs directly targeting RASA4B; however, research tools such as knockout cell lines and antibodies are used to study its function
07
Biomarkers
No established biomarkers for clinical patient selection or efficacy monitoring are reported for RASA4B specifically; Ras pathway activity may provide indirect readouts
Beyond the preview
Go deeper on RAS p21 protein activator 4B (RASA4B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAS p21 protein activator 4B (RASA4B).